Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are widely used in Bhutan to alleviate respiratory problems such as asthma and chronic obstructive pulmonary disease (COPD). The market for these drugs has been steadily growing in recent years, driven by a combination of customer preferences, local special circumstances, and underlying macroeconomic factors.
Customer preferences: Bhutan has a high prevalence of respiratory diseases, with asthma affecting around 10% of the population. This has led to a high demand for bronchodilator drugs, which are commonly used to treat the condition. Customers in Bhutan tend to prefer inhalers over other forms of medication, as they are more convenient and have fewer side effects.
Trends in the market: The market for bronchodilator drugs in Bhutan has been growing steadily in recent years, driven by an increase in the number of people with respiratory diseases. This trend is expected to continue in the coming years, as the country's population continues to grow and age. In addition, the government has been investing in healthcare infrastructure, which is expected to further boost demand for these drugs.
Local special circumstances: Bhutan is a small, mountainous country with a relatively underdeveloped healthcare system. This has led to a reliance on imported drugs, including bronchodilators. However, the government has been working to improve the country's healthcare system, with a focus on increasing access to essential medicines. This is expected to create opportunities for local manufacturers of bronchodilator drugs.
Underlying macroeconomic factors: Bhutan's economy has been growing steadily in recent years, driven by the development of hydropower projects and tourism. This has led to an increase in disposable income and a growing middle class, which is expected to drive demand for healthcare services, including bronchodilator drugs. In addition, the government has been investing in the development of the pharmaceutical industry, which is expected to create opportunities for local manufacturers of these drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
